Drug
Extended-release Galantamine Hydrobromide clinical trials
A product of Galantamine; its studies count on that page too.
Keep track of what changes. Save the Extended-release Galantamine Hydrobromide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2003 (1)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 2
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Northwell Health (1) · Duke University (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- A dosage form of Galantamine
- One of Cholinesterase Inhibitors source
Studies
Open first, then newest update. How each study uses Extended-release Galantamine Hydrobromide is read from its arms, and is right about nine times in ten.
Testing it · 3
- Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)RecruitingPhase 2/3Northwell HealthNCT07625332Written as Galantamine Hydrobromide Extended Release
- Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease PatientsTerminatedPhase 4Duke UniversityNCT00369603Written as Razadyne ER
- A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.CompletedPhase 3Johnson & Johnson Pharmaceutical Research & Development, L.L.C.NCT00077727Written as Extended-release galantamine hydrobromide